Long-term adjunctive rufinamide therapy was beneficial for Lennox–Gastaut syndrome.

Reduction of seizure frequency was maintained to 52 weeks in the extension study.

Of 54 patients, 38 had rufinamide-related adverse events, mainly mild and moderate.

Exacerbation of seizures and poor appetite/weight loss require attention.